Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: A retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages 4492-4499

  Duarte, Rafael F ^a   Canals, Carmen ^a   Onida, Francesco ^a   Gabriel, Ian H ^a   Arranz, Reyes ^a   Arcese, William ^a   Ferrant, Augustin ^a   Kobbe, Guido ^a   Narni, Franco ^a   Deliliers, Giorgio Lambertenghi ^a   Olavarría, Eduardo ^a   Schmitz, Norbert ^a   Sureda, Anna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; PENTOSTATIN; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SEZARY SYNDROME; T CELL DEPLETION; WHOLE BODY RADIATION;

ADULT; AGED; BONE MARROW TRANSPLANTATION; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SEZARY SYNDROME; SKIN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951977960     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.3241     Document Type: Article

References (25)

1. Weinstock MA, Gardstein B: Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 89:1240-1244, 1999 (Pubitemid 29359582)
2. Bradford PT, Devesa SS, Anderson WF, et al: Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood 113:5064-5073, 2009
3. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 88:2385-2409, 1996
4. Willemze R, Jaffe ES, Burg G, et al: WHOEORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
5. Bunn PA Jr, Lamberg SI: Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 63:725-728, 1979
6. Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722, 2007 (Pubitemid 47443880)
7. Arulogun SO, Prince HM, Ng J, et al: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112:3082-3087, 2008
8. Whittaker SJ, Marsden JR, Spittle M, et al: Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Groups guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 149:1095-1107, 2003 (Pubitemid 38058085)
9. Trautinger F, Knobler R, Willemze R, et al: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42:1014-1030, 2006
10. Horwitz SM, Olsen EA, Duvic M, et al: Review of the treatment of mycosis fungoides and sezary syndrome: A stage-based approach. J Natl Compr Canc Netw 6:436-442, 2008 (Pubitemid 351642616)
11. Dummer R, Dreyling M: Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19:ii72-ii76, 2008 (suppl 2)
12. Gardner JM, Evans KG, Musiek A, et al: Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 21:131-137, 2009
13. Duarte RF, Schmitz N, Servitje O, et al: Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 41:597-604, 2008 (Pubitemid 351523997)
14. Wu PA, Kim YH, Lavori PW, et al: A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant 15:982-990, 2009
15. Carrié E, Buzyn A, Fraitag S, et al: Transformed juvenile-onset mycosis fungoides: Treatment by bone marrow transplantation with graft-versuslymphoma effect. Ann Dermatol Venereol 134:471-476, 2007 (Pubitemid 46797781)
16. Gabriel IH, Olavarria E, Jones RR, et al: Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant 40:401-403, 2007 (Pubitemid 47202430)
17. Soligo D, Ibatici A, Berti E, et al: Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant 31:663-666, 2003 (Pubitemid 36553476)
18. van Besien K, Loberiza FR Jr, Bajorunaite R, et al: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003 (Pubitemid 37409366)
19. Gratwohl A, Stern M, Brand R, et al: Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. Cancer 115:4715-4726, 2009
20. Labopin M, Iacobelli S: Statistical Guidelines for EBMT, 2003. http://www.ebmt.org
21. Burt RK, Guitart J, Traynor A, et al: Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft-versus-tumor effect. Bone Marrow Transplant 25:111-113, 2000 (Pubitemid 30093166)
22. Herbert KE, Spencer A, Grigg A, et al: Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 34:521-525, 2004 (Pubitemid 39264043)
23. Molina A, Zain J, Arber DA, et al: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. J Clin Oncol 23:6163-6171, 2005
24. Peggs KS, Hunter A, Chopra R, et al: Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:1934-1941, 2005
25. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462, 2008 (Pubitemid 351171699)